Isolated Myocardial Metastases in a Neuroendocrine Tumor: 68 Ga-DOTATATE PET/CT and Cardiac Magnetic Resonance Imaging Findings.

Clin Nucl MedApr 2, 2026 (epub)
Case ReportOncology (Medical)Cardiology

Muhammet Halil Baltacioglu, Pelin Sahin Oguz

✦ AI-curated · Sources linked

Case in brief

A 58-year-old man with a well-differentiated grade 1 terminal ileum neuroendocrine tumor (Ki-67 1%) underwent 68Ga-DOTATATE PET/CT for staging. Imaging showed intense uptake in the primary tumor and two incidental myocardial foci. Cardiac magnetic resonance imaging demonstrated signal heterogeneity at the corresponding sites, supporting myocardial metastases. The findings established isolated myocardial involvement at initial staging.

What made this case unusual

Myocardial metastases were detected at initial staging as isolated cardiac involvement, rather than in the setting of advanced metastatic disease described as typical in the report.

Diagnostic / clinical pearl

Incidental myocardial foci on somatostatin receptor-based PET/CT in a patient with a neuroendocrine tumor may warrant correlation with cardiac magnetic resonance imaging to assess for metastases.

Source

PubMed · PMID 41949898

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.